Global Autoimmune and Inflammatory Immunomodulators market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Get Access Now!

Global Autoimmune and Inflammatory Immunomodulators Market Size and Outlook 2025-31

The global Autoimmune and Inflammatory Immunomodulators market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. United States market for Autoimmune and Inflammatory Immunomodulators is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. China market for Autoimmune and Inflammatory Immunomodulators is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Europe market for Autoimmune and Inflammatory Immunomodulators is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Global key Autoimmune and Inflammatory Immunomodulators players cover AbbVie, Johnson & Johnson, Amgen, F. Hoffmann-La Roche, Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024. Infinity Market Research newest research report, the Autoimmune and Inflammatory Immunomodulators Industry Forecast looks at past sales and reviews total world Autoimmune and Inflammatory Immunomodulators sales in 2024, providing a comprehensive analysis by region and market sector of projected Autoimmune and Inflammatory Immunomodulators sales for 2025 through 2031. With Autoimmune and Inflammatory Immunomodulators sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Autoimmune and Inflammatory Immunomodulators industry. This Insight Report provides a comprehensive analysis of the global Autoimmune and Inflammatory Immunomodulators landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Autoimmune and Inflammatory Immunomodulators portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Autoimmune and Inflammatory Immunomodulators market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Autoimmune and Inflammatory Immunomodulators and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Autoimmune and Inflammatory Immunomodulators. This report presents a comprehensive overview, market shares, and growth opportunities of Autoimmune and Inflammatory Immunomodulators market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Biologics &nbsp;&nbsp;&nbsp; Small Molecules Segmentation by Application: &nbsp;&nbsp;&nbsp; Rheumatoid Arthritis &nbsp;&nbsp;&nbsp; IBD This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; AbbVie &nbsp;&nbsp;&nbsp; Johnson & Johnson &nbsp;&nbsp;&nbsp; Amgen &nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche &nbsp;&nbsp;&nbsp; Pfizer &nbsp;&nbsp;&nbsp; AstraZeneca &nbsp;&nbsp;&nbsp; Avaxia Biologics &nbsp;&nbsp;&nbsp; Biogen Idec &nbsp;&nbsp;&nbsp; Bristol-Myers Squibb &nbsp;&nbsp;&nbsp; Boehringer Ingelheim &nbsp;&nbsp;&nbsp; Eli Lilly &nbsp;&nbsp;&nbsp; Enlivex Therapeutics &nbsp;&nbsp;&nbsp; Gilead Sciences Key Questions Addressed in this Report What is the 10-year outlook for the global Autoimmune and Inflammatory Immunomodulators market? What factors are driving Autoimmune and Inflammatory Immunomodulators market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Autoimmune and Inflammatory Immunomodulators market opportunities vary by end market size? How does Autoimmune and Inflammatory Immunomodulators break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Autoimmune and Inflammatory Immunomodulators Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Autoimmune and Inflammatory Immunomodulators by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Autoimmune and Inflammatory Immunomodulators by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Autoimmune and Inflammatory Immunomodulators Segment by Type &nbsp;2.2.1 Biologics &nbsp;2.2.2 Small Molecules &nbsp;2.3 Autoimmune and Inflammatory Immunomodulators Sales by Type &nbsp;2.3.1 Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Autoimmune and Inflammatory Immunomodulators Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Autoimmune and Inflammatory Immunomodulators Sale Price by Type (2020-2025) &nbsp;2.4 Autoimmune and Inflammatory Immunomodulators Segment by Application &nbsp;2.4.1 Rheumatoid Arthritis &nbsp;2.4.2 IBD &nbsp;2.5 Autoimmune and Inflammatory Immunomodulators Sales by Application &nbsp;2.5.1 Global Autoimmune and Inflammatory Immunomodulators Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Autoimmune and Inflammatory Immunomodulators Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Autoimmune and Inflammatory Immunomodulators Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Autoimmune and Inflammatory Immunomodulators Breakdown Data by Company &nbsp;3.1.1 Global Autoimmune and Inflammatory Immunomodulators Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Autoimmune and Inflammatory Immunomodulators Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Autoimmune and Inflammatory Immunomodulators Revenue by Company (2020-2025) &nbsp;3.2.2 Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Autoimmune and Inflammatory Immunomodulators Sale Price by Company &nbsp;3.4 Key Manufacturers Autoimmune and Inflammatory Immunomodulators Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Autoimmune and Inflammatory Immunomodulators Product Location Distribution &nbsp;3.4.2 Players Autoimmune and Inflammatory Immunomodulators Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Autoimmune and Inflammatory Immunomodulators by Geographic Region &nbsp;4.1 World Historic Autoimmune and Inflammatory Immunomodulators Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Autoimmune and Inflammatory Immunomodulators Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Autoimmune and Inflammatory Immunomodulators Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Autoimmune and Inflammatory Immunomodulators Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Autoimmune and Inflammatory Immunomodulators Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Autoimmune and Inflammatory Immunomodulators Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Autoimmune and Inflammatory Immunomodulators Sales Growth &nbsp;4.4 APAC Autoimmune and Inflammatory Immunomodulators Sales Growth &nbsp;4.5 Europe Autoimmune and Inflammatory Immunomodulators Sales Growth &nbsp;4.6 Middle East & Africa Autoimmune and Inflammatory Immunomodulators Sales Growth 5 Americas &nbsp;5.1 Americas Autoimmune and Inflammatory Immunomodulators Sales by Country &nbsp;5.1.1 Americas Autoimmune and Inflammatory Immunomodulators Sales by Country (2020-2025) &nbsp;5.1.2 Americas Autoimmune and Inflammatory Immunomodulators Revenue by Country (2020-2025) &nbsp;5.2 Americas Autoimmune and Inflammatory Immunomodulators Sales by Type (2020-2025) &nbsp;5.3 Americas Autoimmune and Inflammatory Immunomodulators Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Autoimmune and Inflammatory Immunomodulators Sales by Region &nbsp;6.1.1 APAC Autoimmune and Inflammatory Immunomodulators Sales by Region (2020-2025) &nbsp;6.1.2 APAC Autoimmune and Inflammatory Immunomodulators Revenue by Region (2020-2025) &nbsp;6.2 APAC Autoimmune and Inflammatory Immunomodulators Sales by Type (2020-2025) &nbsp;6.3 APAC Autoimmune and Inflammatory Immunomodulators Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Autoimmune and Inflammatory Immunomodulators by Country &nbsp;7.1.1 Europe Autoimmune and Inflammatory Immunomodulators Sales by Country (2020-2025) &nbsp;7.1.2 Europe Autoimmune and Inflammatory Immunomodulators Revenue by Country (2020-2025) &nbsp;7.2 Europe Autoimmune and Inflammatory Immunomodulators Sales by Type (2020-2025) &nbsp;7.3 Europe Autoimmune and Inflammatory Immunomodulators Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Autoimmune and Inflammatory Immunomodulators by Country &nbsp;8.1.1 Middle East & Africa Autoimmune and Inflammatory Immunomodulators Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Autoimmune and Inflammatory Immunomodulators Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Autoimmune and Inflammatory Immunomodulators Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Autoimmune and Inflammatory Immunomodulators Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Autoimmune and Inflammatory Immunomodulators &nbsp;10.3 Manufacturing Process Analysis of Autoimmune and Inflammatory Immunomodulators &nbsp;10.4 Industry Chain Structure of Autoimmune and Inflammatory Immunomodulators 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Autoimmune and Inflammatory Immunomodulators Distributors &nbsp;11.3 Autoimmune and Inflammatory Immunomodulators Customer 12 World Forecast Review for Autoimmune and Inflammatory Immunomodulators by Geographic Region &nbsp;12.1 Global Autoimmune and Inflammatory Immunomodulators Market Size Forecast by Region &nbsp;12.1.1 Global Autoimmune and Inflammatory Immunomodulators Forecast by Region (2026-2031) &nbsp;12.1.2 Global Autoimmune and Inflammatory Immunomodulators Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Autoimmune and Inflammatory Immunomodulators Forecast by Type (2026-2031) &nbsp;12.7 Global Autoimmune and Inflammatory Immunomodulators Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 AbbVie &nbsp;13.1.1 AbbVie Company Information &nbsp;13.1.2 AbbVie Autoimmune and Inflammatory Immunomodulators Product Portfolios and Specifications &nbsp;13.1.3 AbbVie Autoimmune and Inflammatory Immunomodulators Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 AbbVie Main Business Overview &nbsp;13.1.5 AbbVie Latest Developments &nbsp;13.2 Johnson & Johnson &nbsp;13.2.1 Johnson & Johnson Company Information &nbsp;13.2.2 Johnson & Johnson Autoimmune and Inflammatory Immunomodulators Product Portfolios and Specifications &nbsp;13.2.3 Johnson & Johnson Autoimmune and Inflammatory Immunomodulators Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Johnson & Johnson Main Business Overview &nbsp;13.2.5 Johnson & Johnson Latest Developments &nbsp;13.3 Amgen &nbsp;13.3.1 Amgen Company Information &nbsp;13.3.2 Amgen Autoimmune and Inflammatory Immunomodulators Product Portfolios and Specifications &nbsp;13.3.3 Amgen Autoimmune and Inflammatory Immunomodulators Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Amgen Main Business Overview &nbsp;13.3.5 Amgen Latest Developments &nbsp;13.4 F. Hoffmann-La Roche &nbsp;13.4.1 F. Hoffmann-La Roche Company Information &nbsp;13.4.2 F. Hoffmann-La Roche Autoimmune and Inflammatory Immunomodulators Product Portfolios and Specifications &nbsp;13.4.3 F. Hoffmann-La Roche Autoimmune and Inflammatory Immunomodulators Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 F. Hoffmann-La Roche Main Business Overview &nbsp;13.4.5 F. Hoffmann-La Roche Latest Developments &nbsp;13.5 Pfizer &nbsp;13.5.1 Pfizer Company Information &nbsp;13.5.2 Pfizer Autoimmune and Inflammatory Immunomodulators Product Portfolios and Specifications &nbsp;13.5.3 Pfizer Autoimmune and Inflammatory Immunomodulators Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Pfizer Main Business Overview &nbsp;13.5.5 Pfizer Latest Developments &nbsp;13.6 AstraZeneca &nbsp;13.6.1 AstraZeneca Company Information &nbsp;13.6.2 AstraZeneca Autoimmune and Inflammatory Immunomodulators Product Portfolios and Specifications &nbsp;13.6.3 AstraZeneca Autoimmune and Inflammatory Immunomodulators Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 AstraZeneca Main Business Overview &nbsp;13.6.5 AstraZeneca Latest Developments &nbsp;13.7 Avaxia Biologics &nbsp;13.7.1 Avaxia Biologics Company Information &nbsp;13.7.2 Avaxia Biologics Autoimmune and Inflammatory Immunomodulators Product Portfolios and Specifications &nbsp;13.7.3 Avaxia Biologics Autoimmune and Inflammatory Immunomodulators Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Avaxia Biologics Main Business Overview &nbsp;13.7.5 Avaxia Biologics Latest Developments &nbsp;13.8 Biogen Idec &nbsp;13.8.1 Biogen Idec Company Information &nbsp;13.8.2 Biogen Idec Autoimmune and Inflammatory Immunomodulators Product Portfolios and Specifications &nbsp;13.8.3 Biogen Idec Autoimmune and Inflammatory Immunomodulators Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Biogen Idec Main Business Overview &nbsp;13.8.5 Biogen Idec Latest Developments &nbsp;13.9 Bristol-Myers Squibb &nbsp;13.9.1 Bristol-Myers Squibb Company Information &nbsp;13.9.2 Bristol-Myers Squibb Autoimmune and Inflammatory Immunomodulators Product Portfolios and Specifications &nbsp;13.9.3 Bristol-Myers Squibb Autoimmune and Inflammatory Immunomodulators Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Bristol-Myers Squibb Main Business Overview &nbsp;13.9.5 Bristol-Myers Squibb Latest Developments &nbsp;13.10 Boehringer Ingelheim &nbsp;13.10.1 Boehringer Ingelheim Company Information &nbsp;13.10.2 Boehringer Ingelheim Autoimmune and Inflammatory Immunomodulators Product Portfolios and Specifications &nbsp;13.10.3 Boehringer Ingelheim Autoimmune and Inflammatory Immunomodulators Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Boehringer Ingelheim Main Business Overview &nbsp;13.10.5 Boehringer Ingelheim Latest Developments &nbsp;13.11 Eli Lilly &nbsp;13.11.1 Eli Lilly Company Information &nbsp;13.11.2 Eli Lilly Autoimmune and Inflammatory Immunomodulators Product Portfolios and Specifications &nbsp;13.11.3 Eli Lilly Autoimmune and Inflammatory Immunomodulators Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 Eli Lilly Main Business Overview &nbsp;13.11.5 Eli Lilly Latest Developments &nbsp;13.12 Enlivex Therapeutics &nbsp;13.12.1 Enlivex Therapeutics Company Information &nbsp;13.12.2 Enlivex Therapeutics Autoimmune and Inflammatory Immunomodulators Product Portfolios and Specifications &nbsp;13.12.3 Enlivex Therapeutics Autoimmune and Inflammatory Immunomodulators Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 Enlivex Therapeutics Main Business Overview &nbsp;13.12.5 Enlivex Therapeutics Latest Developments &nbsp;13.13 Gilead Sciences &nbsp;13.13.1 Gilead Sciences Company Information &nbsp;13.13.2 Gilead Sciences Autoimmune and Inflammatory Immunomodulators Product Portfolios and Specifications &nbsp;13.13.3 Gilead Sciences Autoimmune and Inflammatory Immunomodulators Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 Gilead Sciences Main Business Overview &nbsp;13.13.5 Gilead Sciences Latest Developments 14 Research Findings and Conclusion

Report	Global Autoimmune and Inflammatory Immunomodulators Market Growth 2025-2031
Selected License	Multi ID: LPI23620

Buyer Information

Order Summary